Medical News

RSS

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.

7 Jul 2010

Retin-A Micro Pump combines tretinoin for treating acne: Study

From the minute they wake until the minute they sleep, today's teenagers have busy, demanding schedules. Life may be hectic, but an acne care routine doesn't have to get in the way, according to a new study published in the July 2010 issue of Journal of Drugs in Dermatology.

7 Jul 2010

Apicore files DMF for Fondaparinux Sodium API with U.S. FDA

Apicore LLC announced today that they filed a drug master file (DMF) for Fondaparinux Sodium active pharmaceutical ingredient (API) with the U.S. Food and Drug Administration (FDA) on June 28, 2010.

7 Jul 2010

Dehaier Medical Systems reaffirms earlier earnings estimate for fiscal 2010

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today reaffirmed the company's earlier earnings estimate of $0.80 EPS for fiscal year 2010.

7 Jul 2010

Virginia Hospital Center selects CredenceHealth to provide best quality of care for patients

CredenceHealth, a provider of real-time clinical intelligence for hospitals and health plans, announced today that Virginia Hospital Center , a 342-bed not-for-profit hospital in Arlington, Virginia, has selected CredenceHealth for the hospital's latest patient quality improvement initiative.

7 Jul 2010

HTA acquires $13.5M medical office portfolio in Texas

Healthcare Trust of America, Inc., a self-managed, non-traded real estate investment trust, announced the purchase of a medical office portfolio located in Denton, Texas and Lewisville, Texas for approximately $13,500,000.

7 Jul 2010

Researchers show unexpected, physiological effects of water

Name a drink that can make you more alert for late-night studying, prevent you from fainting after giving blood, and even promote a teensy bit of weight loss. Chances are you didn't say water. But that's the right answer.

7 Jul 2010

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the company will pursue a Phase 3 clinical program for its autologous cell therapy for the treatment of critical limb ischemia (CLI) through the U.S. Food and Drug Administration's special protocol assessment (SPA) process. Aastrom is currently completing a Phase 2b clinical trial of its cell therapy in patients with CLI and recently met with FDA officials to discuss plans for the Phase 3 program.

7 Jul 2010

Anxiety can cause individuals become more idealistic in religious belief, researchers find

Anxiety and uncertainty can cause us to become more idealistic and more radical in our religious beliefs, according to new findings by York University researchers, published in this month's issue of the Journal of Personality and Social Psychology.

7 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

Medifast announces grand opening of Texas Distribution Center in Coppell

Medifast, Inc. today announced the grand opening of a 50,000 square foot Texas Distribution Center located in Coppell, Tx., just outside of Dallas. The facility will support West Coast shipping for Medifast Direct; Take Shape For Life, Medifast's personal coaching division; and Medifast Weight Control Centers.

7 Jul 2010

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.

7 Jul 2010

KHN column – Insuring your health: Should patients get contraceptives from health plans at no cost?

"The average American woman who wants two children spends roughly five years trying to get pregnant or being pregnant. She spends a much longer time - 30 years, on average - trying to avoid pregnancy, often at no small expense. That may soon change, at least the expense part" (7/6).

7 Jul 2010

Initial Phase II study results of ofatumumab in patients with RRMS announced

Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis.

7 Jul 2010

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

E. Fougera & Co., a leading specialty pharmaceutical manufacturer, announced it has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx). Fougera's Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA has granted to Fougera this year.

7 Jul 2010

Cambridge Heart commences enrollment in study to identify ischemia in patients with coronary artery disease

Cambridge Heart, Inc., today announced the first patient enrollments in the MTWA-CAD study (Evaluation of Microvolt T-Wave Alternans Testing for the Detection of Active Ischemia in Patients with Known or Suspected Coronary Artery Disease).

7 Jul 2010

MJFF teams up with EHE International to raise awareness of Parkinson's disease

The Michael J. Fox Foundation for Parkinson's Research is teaming up with EHE International to raise awareness of the fight against Parkinson's disease. For the month of July, EHE International has kindly donated a 115-square-foot window space at 10 Rockefeller Plaza to showcase the many ways ordinary citizens can support the Foundation through its grassroots fundraising arm, Team Fox.

7 Jul 2010

FDA approves IMT to improve vision in patients with end-stage AMD

The U.S. Food and Drug Administration today announced it has approved the Implantable Miniature Telescope to improve vision in some patients with end-stage age-related macular degeneration.

7 Jul 2010

Study finds additional targets for new therapies to treat advanced prostate cancer patients

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

7 Jul 2010

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.

7 Jul 2010

Medical News

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Retin-A Micro Pump combines tretinoin for treating acne: Study

Apicore files DMF for Fondaparinux Sodium API with U.S. FDA

Dehaier Medical Systems reaffirms earlier earnings estimate for fiscal 2010

Virginia Hospital Center selects CredenceHealth to provide best quality of care for patients

HTA acquires $13.5M medical office portfolio in Texas

Researchers show unexpected, physiological effects of water

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Anxiety can cause individuals become more idealistic in religious belief, researchers find

QIAGEN receives CE conformity marking for careHPV Test

Medifast announces grand opening of Texas Distribution Center in Coppell

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

KHN column – Insuring your health: Should patients get contraceptives from health plans at no cost?

Initial Phase II study results of ofatumumab in patients with RRMS announced

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

Cambridge Heart commences enrollment in study to identify ischemia in patients with coronary artery disease

MJFF teams up with EHE International to raise awareness of Parkinson's disease

FDA approves IMT to improve vision in patients with end-stage AMD

Study finds additional targets for new therapies to treat advanced prostate cancer patients

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News